Algorithms for the treatment of patients with chronic cerebral ischemia of stages I and II with use of Picamilon: results of an open clinical comparative study
Notice bibliographique
Résumé
Aim. To study the efficacy and safety of Picamilon in patients with stages I and II of chronic cerebral ischemia (CCI). Materials and methods. An open comparative clinical trial included 100 patients who were divided into 2 groups depending on the stage of CCI: n=50 (group 1 with CCI stage I); n=50 (group 2 with CCI stage II, average age 62.2±8.98 years). Group 1 patients were also divided into subgroups 1A (mean age 55.6±6.76 years) and 1B (mean age 52.8±6.11 years), which used different treatment regimens. The patients were prescribed the drug Picamilon, the total duration of therapy in group 1 was 60 days, in group 2 – 70 days. The study included 4 visits: before treatment, 10 days later, at the end of therapy (60/70 days later), 1.5 months after the end of treatment. The study was conducted using the Montreal Cognitive Function Assessment Scale (MoCA), the A.M. Wein scale of autonomic disorders, the A.I. Fedin scale of neurological disorders, and the Ya.I. Levin Sleep Quality Scale. The condition of cerebral blood flow (Dopplerography of intracranial vessels) and endothelial function (levels of methylated forms of arginine – ADMA, MMA, SDMA and their ratios) were assessed. Adverse events on the background of therapy and the tolerability of treatment were recorded. Results. During treatment, statistically significant cognitive improvement on the MoCA scale (p=0.022 and p0.0001) was observed in groups of patients with different stages of CCI, increasing in the delayed period: more than 80% of patients in the general sample reached the normal level when assessed in the long-term period. Patients with CCI II initially have a worse cognitive status, while their average score growth is significantly higher compared to CCI I. Autonomic symptoms significantly decrease, regardless of the stage of CCI and the treatment regimen: improvement in 29% and 38% of patients with CCI stages I and II, respectively. Positive dynamics of neurological functions was noted in 77% (CCI I) and 84% (CCI II) of patients, the effect of treatment increases in the delayed period (p0.05). Patients with CCI II initially have a more pronounced neurological deficit, however, during treatment, the average decrease on the CCI Fedin A.I. scale is statistically significantly higher (p=0.037) than in patients with CCI I. In both groups of patients, there is a statistically significant comparable positive trend (decrease) in the severity of sleep disorders, increasing in the delayed period. In subgroup 1B (with parenteral therapy at the start), 28% of patients improved sleep quality by Visit 2 compared to 11% in subgroup 1A, and by the end of the course of therapy (Visit 3), the effect in the groups was comparable. The majority of patients (98%) noted good tolerability and comfort of therapy, while the groups and subgroups did not differ (p0.05). Picamilon has an effect on cerebral hemodynamic parameters: against the background of therapy, the proportion of patients who have achieved normalization of hemodynamic parameters increases: up to 100% when assessing Vmax and resistance index and up to 93% when assessing pulsation index; the thickness of the intimate media complex is significantly reduced. Picamilon reduces concentrations of markers of endothelial dysfunction – initially elevated levels of ADMA in both groups and SDMA in group 2. Conclusion. The use of Picamilon is effective in patients with stages I and II CCI, contributes to significant regression of cognitive impairment, neurological deficit, improvement of sleep quality and stabilization of autonomic function; improves vascular endothelial function, reduces the risk of atherosclerosis and cardiovascular complications in patients. The optimal duration of Picamilon therapy in CCI is 2–2.5 months, depending on the stage of the disease.
Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.
Comment cette classification a été obtenuedéplier
Prédiction distillée sur la base complète
Imitation des enseignantsNi prévalence calibrée, ni vérité terrain. Validation humaine à venir. Apprise à partir de 10 348 étiquettes directes de Codex et de 10 348 étiquettes directes de Gemma. Le mode candidate est l'union des têtes enseignantes seuillées; le consensus est leur intersection. Ces sorties portent le statut machine_predicted_unvalidated et ne sont ni des étiquettes humaines ni des étiquettes directes de modèles de pointe.
Scores Codex et Gemma par catégorie
| Catégorie | Codex | Gemma |
|---|---|---|
| Métarecherche | 0,000 | 0,000 |
| Méta-épidémiologie (sens strict) | 0,000 | 0,000 |
| Méta-épidémiologie (sens large) | 0,001 | 0,000 |
| Bibliométrie | 0,000 | 0,000 |
| Études des sciences et des technologies | 0,000 | 0,001 |
| Communication savante | 0,000 | 0,000 |
| Science ouverte | 0,000 | 0,000 |
| Intégrité de la recherche | 0,000 | 0,000 |
| Charge utile insuffisante (le modèle a refusé de juger) | 0,000 | 0,000 |
Scores machine (provisoires)
Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.
Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.
score_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découleClassification
machine, non validéePrédiction automatique; un appel candidat d’une seule tête enseignante, pas un consensus.
Le détail, modèle par modèle et score par score, se trouve en fin de page sous « Comment cette classification a été obtenue ».